A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of 9MW3011 in Chinese patients with Polycythemia Vera（PV）.
Polycythemia Vera
DRUG: 9MW3011
Adverse Event, Incidence of adverse events, Up to 141 or 197 days|Vital sign, Incidence of treatment-emergent clinically abnormal vital signs, Up to 141 or 197 days|Physical examination, Incidence of treatment-emergent clinically abnormal physical examinations, Up to 141 or 197 days|12-lead electrocardiogram (ECG), Incidence of treatment-emergent clinically significant 12-lead electrocardiograms (ECGs), Up to 141 or 197 days|Laboratory test result, Incidence of treatment-emergent clinically significant laboratory test results, Up to 141 or 197 days
Cmax, Plasma maximum measured drug concentration, Day 1 to Day 141 or 197|Tmax, Time of maximum concentration, Day 1 to Day 141 or 197|AUC0-τ, Area under the plasma concentration-time curve during a dosage interval（τ）, Day 1 to Day 141 or 197|AUC0-t, Area under the concentration-time curve from dosing to the last measurable time point, Day 1 to Day 141 or 197|AUC0-∞, Area under the concentration-time curve from dosing to infinity, Day 1 to Day 141 or 197|λz, Terminal elimination rate constant, Day 1 to Day 141 or 197|t1/2z, The terminal elimination half-life, Day 1 to Day 141 or 197|MRT, Mean residence time, Day 1 to Day 141 or 197|Vss, Volume of Distribution at Steady State, Day 1 to Day 141 or 197|CLss, Steady-state clearance, Day 1 to Day 141 or 197|DF, Fluctuation percentage, Day 1 to Day 141 or 197|Ctrough, Trough Concentration, Day 1 to Day 141 or 197|Rac(AUC), Accumulation ratio calculated from the AUCτ,ss and AUCτ after single dosing, Day 1 to Day 141 or 197|Rac(cmax), Accumulation ratio calculated from the Cmax,ss and Cmax after single dosing, Day 1 to Day 141 or 197|Hepcidin, Change from baseline in hepcidin levels, Day 1 to Day 141 or 197|Serum iron, Change from baseline in serum iron levels, Day 1 to Day 141 or 197|Transferrin saturation (TSAT), Change from baseline in transferrin saturation (TSAT) levels, Day 1 to Day 141 or 197|Anti-drug antibodies(ADA), The incidence of ADA, Day 1 to Day 141 or 197|Hematocrit (HCT), Change from baseline in HCT levels, Day1 to Day 141 or 197|Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score（MPN-SAF TSS）, Change from baseline in MPN-SAF TSS score, Day 1 to Day 141 or 197
The multiple dose fo the starting dose cohorts will comprise 3 dose cohorts of 8 PV subjects each.In each cohort, subjects will receive 9MW3011 via intravenous infusion.A decision on whether to proceed with case expansion and dose escalation will be based on the safety and PK-PD data.